|
1.
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2.
|
Yonemura Y, Sugiyama K, Fushida S, Kamata
T, Ohoyama S, Kimura H, Yamaguchi A and Miyazaki I: Tissue status
of epidermal growth factor and its receptor as an indicator of poor
prognosis in patients with gastric cancer. Anal Cell Pathol.
3:343–350. 1991.PubMed/NCBI
|
|
3.
|
Hirono Y, Tsugawa K, Fushida S, Ninomiya
I, Yonemura Y, Miyazaki I, Endou Y, Tanaka M and Sasaki T:
Amplification of epidermal growth factor receptor gene and its
relationship to survival in human gastric cancer. Oncology.
52:182–188. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Allgayer H, Babic R, Gruetzner KU,
Tarabichi A, Schildberg FW and Heiss MM: c-erbB-2 is of independent
prognostic relevance in gastric cancer and is associated with the
expression of tumor-associated protease systems. J Clin Oncol.
18:2201–2209. 2000.PubMed/NCBI
|
|
5.
|
García I, Vizoso F, Martín A, Sanz L,
Abdel-Lah O, Raigoso P and García-Muñiz JL: Clinical significance
of the epidermal growth factor receptor and HER2 receptor in
resectable gastric cancer. Ann Surg Oncol. 10:234–241.
2003.PubMed/NCBI
|
|
6.
|
Hirashima Y, Yamada Y, Matsubara J,
Takahari D, Okita N, Takashima A, Kato K, Hamaguchi T, Shirao K,
Shimada Y, Taniguchi H and Shimoda T: Impact of vascular
endothelial growth factor receptor 1, 2, and 3 expression on the
outcome of patients with gastric cancer. Cancer Sci. 100:310–315.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Jüttner S, Wissmann C, Jöns T, Vieth M,
Hertel J, Gretschel S, Schlag PM, Kemmner W and Höcker M: Vascular
endothelial growth factor-D and its receptor VEGFR-3: two novel
independent prognostic markers in gastric adenocarcinoma. J Clin
Oncol. 24:228–240. 2006.PubMed/NCBI
|
|
8.
|
Hayashi M, Inokuchi M, Takagi Y, Yamada H,
Kojima K, Kumagai J, Kawano T and Sugihara K: High expression of
HER3 is associated with a decreased survival in gastric cancer.
Clin Cancer Res. 14:7843–7849. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Bang YJ, van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J and Kang YK; for
the ToGA Trial Investigators: Trastuzumab in combination with
chemotherapy versus chemotherapy alone for treatment of
HER2-positive advanced gastric or gastro-oesophageal junction
cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Lancet. 376:687–697. 2010. View Article : Google Scholar
|
|
10.
|
Grandis JR, Drenning SD, Chakraborty A,
Zhou MY, Zeng Q, Pitt AS and Tweardy DJ: Requirement of Stat3 but
not Stat1 activation for epidermal growth factor receptor-mediated
cell growth in vitro. J Clin Invest. 102:1385–1392. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Coffer PJ and Kruijer W: EGF receptor
deletions define a region specifically mediating STAT transcription
factor activation. Biochem Biophys Res Commun. 210:74–81. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Schmelzle T and Hall MN: TOR, a central
controller of cell growth. Cell. 103:253–262. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Petroulakis E, Mamane Y, Le Bacquer O,
Shahbazian D and Sonenberg N: mTOR signaling: implications for
cancer and anticancer therapy. Br J Cancer. 94:195–199. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Murayama T, Inokuchi M, Takagi Y, Yamada
H, Kojima K, Kumagai J, Kawano T and Sugihara K: Relation between
outcomes and localisation of p-mTOR expression in gastric cancer.
Br J Cancer. 100:782–788. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Bowman T, Garcia R, Turkson J and Jove R:
STATs in oncogenesis. Oncogene. 15:2474–2488. 2000. View Article : Google Scholar
|
|
16.
|
Levy DE and Lee CK: What does Stat3 do? J
Clin Invest. 109:1143–1148. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Yakata Y, Nakayama T, Yoshizaki A, Kusaba
T, Inoue K and Sekine I: Expression of p-STAT3 in human gastric
carcinoma: significant correlation in tumour invasion and
prognosis. Int J Oncol. 30:437–442. 2007.PubMed/NCBI
|
|
18.
|
Kim DY, Cha ST, Ahn DH, Kang HY, Kwon CI,
Ko KH, Hwang SG, Park PW, Rim KS and Hong SP: STAT3 expression in
gastric cancer indicates a poor prognosis. J Gastroenterol Hepatol.
24:646–651. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Lee J, Kang WK, Park JO, Park SH, Park YS,
Lim HY, Kim J, Kong J, Choi MG, Sohn TS, Noh JH, Bae JM, Kim S, Lim
do H, Kim KM and Park CK: Expression of activated signal transducer
and activator of transcription 3 predicts poor clinical outcome in
gastric adenocarcinoma. APMIS. 117:598–606. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Kusaba T, Nakayama T, Yamazumi K, Yakata
Y, Yoshizaki A, Inoue K, Nagayasu T and Sekine I: Expression of
p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation
with clinicopathological factors. J Clin Pathol. 58:833–838. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Park JK, Hong R, Kim KJ, Lee TB and Lim
SC: Significance of p-STAT3 expression in human colorectal
adenocarcinoma. Oncol Rep. 20:597–604. 2008.PubMed/NCBI
|
|
22.
|
Kim HS, Park YH, Lee J, Ahn JS, Kim J,
Shim YM, Kim JH, Park K, Han J and Ahn MJ: Clinical impact of
phosphorylated signal transducer and activator of transcription 3,
epidermal growth factor receptor, p53, and vascular endothelial
growth factor receptor 1 expression in resected adenocarcinoma of
lung by using tissue microarray. Cancer. 116:676–685. 2010.
View Article : Google Scholar
|
|
23.
|
Haura EB, Zheng Z, Song L, Cantor A and
Bepler G: Activated epidermal growth factor receptor-Stat-3
signaling promotes tumor survival in vivo in non-small cell lung
cancer. Clin Cancer Res. 11:8288–8294. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Sheen-Chen SM, Huang CC, Tang RP, Chou FF
and Eng HL: Prognostic value of signal transducers and activators
of transcription 3 in breast cancer. Cancer Epidemiol Biomarkers
Prev. 17:2286–2290. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Lin SY, Makino K, Xia W, Matin A, Wen Y,
Kwong KY, Bourguignon L and Hung MC: Nuclear localization of EGF
receptor and its potential new role as a transcription factor. Nat
Cell Biol. 3:802–808. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia
W, Wei Y, Bartholomeusz G, Shih JY and Hung MC: Nuclear interaction
of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer
Cell. 7:575–589. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Pinto C, Di Fabio F, Barone C, Siena S,
Falcone A, Cascinu S, Rojas Llimpe FL, Stella G, Schinzari G,
Artale S, Mutri V, Giaquinta S, Giannetta L, Bardelli A and Martoni
AA: Phase II study of cetuximab in combination with cisplatin and
docetaxel in patients with untreated advanced gastric or
gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J
Cancer. 101:1261–1268. 2009. View Article : Google Scholar
|
|
28.
|
Zhou X, Tan M, Stone Hawthorne V, Klos KS,
Lan KH, Yang Y, Yang W, Smith TL, Shi D and Yu D: Activation of the
Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2
overexpression predicts tumor progression in breast cancers. Clin
Cancer Res. 10:6779–6788. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Nam SY, Lee HS, Jung GA, Choi J, Cho SJ,
Kim MK, Kim WH and Lee BL: Akt/PKB activation in gastric carcinomas
correlates with clinicopathologic variables and prognosis. APMIS.
111:1105–1113. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Chadha KS, Khoury T, Yu J, Black JD, Gibbs
JF, Kuvshinoff BW, Tan D, Brattain MG and Javle MM: Activated Akt
and Erk expression and survival after surgery in pancreatic
carcinoma. Ann Surg Oncol. 13:933–939. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Ma J, Meng Y, Kwiatkowski DJ, et al:
Mammalian target of rapamycin regulates murine and human cell
differentiation through STAT3/p63/Jagged/Notch cascade. J Clin
Invest. 120:103–114. 2010. View
Article : Google Scholar : PubMed/NCBI
|
